Dysregulated miRNome of plasmacytoid dendritic cells from patients with Sjögren’s syndrome is associated with processes at the centre of their function
Authors:
- Maarten R HillenMHMaarten R Hillen
- Eleni ChouriECEleni Chouri
- Maojie WangMWMaojie Wang
- Sofie L M BloklandSBSofie L M Blokland
- Aike A KruizeAKAike A Kruize
- Boudewijn M T BurgeringBBBoudewijn M T Burgering
- Marzia RossatoMRMarzia Rossato
- Joel A G van RoonJRJoel A G van Roon
- Timothy R D J RadstakeTRTimothy R D J Radstake
Open Access
- 25 May 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 58 (12) , 2305-2314
Abstract
A considerable body of evidence supports a role for type-I IFN in the pathogenesis of primary SS (pSS). As plasmacytoid dendritic cells (pDCs) are a major source of type-I IFN, we investigated their molecular regulation by measuring expression of a large set of miRNAs. pDCs were isolated from peripheral blood of pSS patients (n = 30) and healthy controls (n = 16) divided into two independent cohorts (discovery and replication). Screening of 758 miRNAs was assessed by an OpenArray quantitative PCR-based technique; replication of a set of identified miRNAs was performed by custom array. Functional annotation of miRNA targets was performed using pathway enrichment. Novel targets of miR-29a and miR-29c were identified using a proteomic approach (stable isotope labelling with amino acids in cell culture). In the discovery cohort, 20 miRNAs were differentially expressed in pSS pDCs compared with healthy control pDCs. Of these, differential expression of 10 miRNAs was confirmed in the replication cohort. The dysregulated miRNAs were involved in phosphoinositide 3-kinase-Ak strain transforming and mammalian target of rapamycin signalling, as well as regulation of cell death. In addition, a set of novel protein targets of miR-29a and miR-29c were identified, including five targets that were regulated by both miRs. The dysregulated miRNome in pDCs of patients with pSS is associated with aberrant regulation of processes at the centre of pDC function, including type-I IFN production and cell death. As miR-29a and miR-29c are pro-apoptotic factors and several of the novel targets identified here are regulators of apoptosis, their downregulation in patients with pSS is associated with enhanced pDC survival.Keywords
Funding Information
- Dutch Arthritis Society (RF-14–2-301, RF-13–2-304)
This publication has 38 references indexed in Scilit:
- Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?RMD Open, 2019
- Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren's syndromeAnnals of the Rheumatic Diseases, 2017
- The multifaceted biology of plasmacytoid dendritic cellsNature Reviews Immunology, 2015
- MicroRNA-29a induces apoptosis via increasing the Bax:Bcl-2 ratio in dermal fibroblasts of patients with systemic sclerosisAutoimmunity, 2015
- Follistatin-Like 1 Attenuates Apoptosis via Disco-Interacting Protein 2 Homolog A/Akt Pathway After Middle Cerebral Artery Occlusion in RatsStroke, 2014
- Type I Interferon Receptor Deficiency Prevents Murine Sjögren’s SyndromeJournal of Dental Research, 2013
- Laminin-1 (LM-111) in preeclampsia and systemic lupus erythematosusAutoimmunity, 2012
- Mammalian Target of Rapamycin Complex 2 (mTORC2) Negatively Regulates Toll-like Receptor 4-mediated Inflammatory Response via FoxO1Journal of Biological Chemistry, 2011
- MicroRNA: Biogenesis, Function and Role in CancerCurrent Genomics, 2010
- Caspase-7: A protease involved in apoptosis and inflammationThe International Journal of Biochemistry & Cell Biology, 2010